Clinical Trial Update: OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating OLIGO-10 stereotactic ablative radiotherapy for metastatic patients with 6 to 10 sites; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Snippet

Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia | Conditions: Metastatic Disease | Phase 2 | Status: RECRUITING